ETON News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

ET

Mkt Cap

$1.47B

Volume

388.86K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

ETON Stock Surges 108% in Six Months: Here's What You Need to KnowEton Pharmaceuticals has gained 108% over six months, driven by 99% Q2 product sales growth and successful Hemangeol relaunch. The company raised 2026 revenue guidance to above $145 million with 35%+ adjusted EBITDA margins. Pipeline expansion including new launches and late-stage candidates like ASN-001 provide additional growth opportunities.Zacks Investment Research · Oct 7, 2026

Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare ConferenceEton Pharmaceuticals announced record Q2 2026 revenue with product sales of $37.6 million, representing 99% year-over-year growth. The company reported GAAP EPS of $0.35 and non-GAAP EPS of $0.43, with EBITDA of $14.1 million. Additionally, Eton expanded its infantile hemangioma franchise by acquiring U.S. rights to ASN-001, a late-stage product candidate targeting moderate infantile hemangiomas, complementing its existing HEMANGEOL product.GlobeNewswire Inc. · Aug 27, 2026

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001Eton Pharmaceuticals has licensed U.S. rights to ASN-001 (timolol topical gel) from Auson Pharmaceuticals for treating moderate infantile hemangiomas. Phase II/III trial results showed 56% elimination rates at week 24 with twice-daily dosing versus 15% for placebo. The company plans to submit an NDA in H2 2027 with potential approval and launch in 2028, targeting an estimated 20,000-30,000 patients annually and positioning ASN-001 as a complementary product to its existing HEMANGEOL therapy.GlobeNewswire Inc. · Aug 5, 2026

Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026Eton Pharmaceuticals announced it will report second quarter 2026 financial results on August 13, 2026, with a conference call at 4:30 p.m. ET. The company also announced a Prior Approval Supplement submission to expand KHINDIVI's indication for a larger pediatric patient population and expanded its rare disease portfolio through commercialization rights to IMPAVIDO®.GlobeNewswire Inc. · Aug 3, 2026

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral SolutionEton Pharmaceuticals announced the acquisition of U.S. commercialization rights to HEMANGEOL® (propranolol hydrochloride) oral solution from Pierre Fabre Medicament. HEMANGEOL is the only FDA-approved treatment for infantile hemangiomas requiring systemic therapy. The acquisition marks Eton's achievement of ten commercial products and is expected to be accretive to 2026 earnings. Commercialization begins May 1st with distribution through Eton's patient support program offering $0 co-pay assistance.Benzinga · Mar 2, 2026

Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral SolutionEton Pharmaceuticals announced FDA approval of DESMODA (desmopressin acetate) Oral Solution for central diabetes insipidus treatment. The product, launching March 9th, is the first FDA-approved oral liquid formulation enabling precise dosing without tablet splitting. Eton projects peak annual sales of $30-50 million with patent protection through 2044, targeting over 13,000 U.S. patients including 3,000-4,000 pediatric patients.GlobeNewswire Inc. · Feb 25, 2026

Eton Pharmaceuticals Reports First Quarter 2024 Financial Results• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth• Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400• Management to hold conference call today at 4:30pm ETGlobeNewswire Inc. · May 9, 2024

Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences ConferenceDEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference in New York as follows:GlobeNewswire Inc. · May 1, 2024

Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak sales of more than $50 million annually -- Product has patent protection through 2043 -GlobeNewswire Inc. · Apr 30, 2024

Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).GlobeNewswire Inc. · Apr 29, 2024

ET

ETONEton Pharmaceutcials, Inc. Common Stock

ETON

Pay with—

Available Balance0.00

Your PositionYou don't own any ETON yet.

Related Tickers

Earnings